Dr. Ofer Sharon, MD and CEO For decades, the field has focused almost exclusively on the tumor—its genetic signatures, mutational burden and molecular drivers. But this narrow lens often falls short in predicting real-world treatment outcomes. It overlooks critical biological processes such as immune response, inflammation, and metabolism, factors that significantly influence whether a patient will benefit from therapy.
OncoHost brings a disruptive view into the picture, introducing a model that sees the patient not as a passive recipient of care, but as a dynamic biological system whose response can guide the course of treatment. That shift drives the company’s mission to capture cancer’s complexity in the host, not just within the tumor, but across the systemic landscape that defines treatment success or failure.
“We believe true precision begins with understanding the full biological context, not just the tumor, but the patient behind it,” says Dr. Ofer Sharon, MD and CEO.
At the core of this approach is PROphet®, an AI-driven platform built on advanced proteomics. Using a single blood sample taken before treatment, PROphet® analyzes thousands of plasma proteins to generate a personalized score. This score delivers three key insights: the likelihood of benefit from PD-1/PD-L1 immunotherapy, the biological reason a patient may not respond, and the potential for severe immune-related side effects.
The added layer of systemic visibility is what sets PROphet® apart from conventional tumor-centric tools like PD-L1 testing or ctDNA. While those offer static molecular snapshots, PROphet® provides a dynamic, real-time understanding of how the patient’s body is responding to cancer and treatment. It offers not just prediction, but biological explanation, helping oncologists understand why a patient may or may not respond to a particular therapy.
The first application of the platform, known as PROphetNSCLC™, supports treatment planning in advanced nonsmall cell lung cancer. The test is designed to complement PD-L1 scoring and existing clinical criteria by introducing a proteomic-based, host biology perspective into the decision-making process. Its clinical utility has been validated through one of the largest prospective trials in immunotherapy and further supported by real-world physician behavior studies.
-
We believe true precision begins with understanding the full biological context, not just the tumor but the patient behind it
The first application of the platform, known as PROphetNSCLC™, supports treatment planning in advanced nonsmall cell lung cancer. The test is designed to complement PD-L1 scoring and existing clinical criteria by introducing a proteomic-based, host biology perspective into the decision-making process. Its clinical utility has been validated through one of the largest prospective trials in immunotherapy and further supported by real-world physician behavior studies.
In a peer-reviewed study published in Clinical Lung Cancer, 100 oncologists were presented with anonymized virtual cases of metastatic NSCLC, each accompanied by PD-L1 expression data. Initially, physicians made treatment decisions based on standard guidelines. After being introduced to PROphetNSCLC™ and re-evaluating the same cases with its score added, 93 percent changed their original recommendations. In a field where every choice can shape survival, that level of impact speaks volumes.
Real-world cases further underscore the clinical value of PROphet®. In one instance, a 66-year-old male with advanced squamous cell carcinoma and a PD-L1 score of 100 percent would typically be treated with PD-1 monotherapy. However, his PROphet® score was negative (2.6), indicating a low likelihood of benefit. Guided by this insight, his physician chose combination chemo-immunotherapy instead, enabling a more appropriate treatment course and improving the potential for a better outcome.
In another case, an 80-year-old woman, hesitant to pursue treatment due to age and brain metastases, saw a shift in perspective after learning she could still benefit from therapy. Though her PD-L1 score was only 10 percent, her PROphet® score was strongly positive (8.3), indicating high likelihood of benefit from combination therapy. The data helped her physician reassure her and proceed with a more personalized treatment plan.
OncoHost’s strength lies in its deep clinical validation. Beyond PROphetNSCLC™, a second test, PROphetirAE™, is currently in development to predict severe immune-related adverse events before they occur. Additional indications are also underway for renal cell carcinoma and melanoma, expanding the platform’s reach across multiple cancer types. This pipeline continues to grow, driven by data partnerships, pharmaceutical collaborations, and a commitment to delivering clinically actionable insights.
By reorienting cancer care around the patient, OncoHost brings full-circle a shift away from tumor-centric precision oncology. As a trusted partner, rooted in a holistic approach and guided by data, OncoHost is advancing the next chapter of personalized cancer care, and redefining what precision truly means.
Choosing Precision Oncology That Can Guide Treatment Decisions
Cancer care has reached a stage where diagnosis alone no longer provides enough information for clinicians to justify therapy selection, pathway design or investment in advanced decision-support systems. Oncology teams already rely on genomic testing, PD-L1 expression analysis, imaging and clinical judgment, yet many patients still receive therapies that deliver limited benefit, create unnecessary toxicity or delay more appropriate treatment options. For executives evaluating precision oncology platforms, the question is no longer whether additional data has value. The more important issue is whether a solution can translate complex biological information into timely guidance that meaningfully influences decisions at the point of care.
The strongest platforms recognize that cancer is not solely driven by the tumor itself. Treatment response is shaped by interactions among the tumor, the patient’s immune system, systemic biology and the therapy being administered. Platforms focused only on static tumor markers may overlook biological conditions that contribute to resistance, treatment benefit or adverse events. A stronger precision oncology model should complement existing biomarkers rather than attempt to replace them, giving clinicians broader biological insight while preserving practical treatment authority.
Evidence quality is equally critical because oncology leaders cannot rely on scientific promise alone. Precision oncology platforms should be supported by prospective clinical data, peer-reviewed validation and transparent connections between platform outputs and treatment decisions. Predictive performance is only part of the value. Clinical teams also need interpretability because a predictive score without biological explanation offers limited utility in multidisciplinary cancer care. Enterprise buyers should therefore prioritize solutions that connect prediction, biological rationale and physician-facing recommendations in a format clinicians can confidently use.
Ease of adoption also matters. Precision oncology tools must align with the pace of real-world cancer treatment, especially when first-line therapy decisions cannot be delayed. Blood-based testing can reduce dependence on tumor tissue access, specimen viability and invasive procedures, but the platform must still provide results quickly enough to influence active treatment windows. Reports should remain concise, clinically relevant and aligned with existing standards of care so physicians can evaluate therapy options without adding unnecessary workflow complexity. Procurement teams should also examine reimbursement alignment, laboratory logistics, turnaround consistency and the level of physician education required to integrate results into consultation, documentation and treatment planning.
The most credible platforms also create value across multiple stakeholders without losing clinical focus. Providers need better tools for therapy selection. Patients need to avoid ineffective treatments and unnecessary risk. Pharmaceutical organizations need stronger patient stratification, trial design support and insight into mechanisms of resistance. The strongest precision oncology solutions create value across all of these groups by clarifying which patients are likely to benefit from therapy, why resistance may occur and where future therapeutic strategies may emerge.
OncoHost stands out because its PROphet® platform approaches precision oncology through plasma proteomic pattern analysis rather than relying exclusively on tumor markers. Its PROphetNSCLC® test supports first-line immunotherapy decision-making for advanced unresectable non-small cell lung cancer using a pre-treatment blood sample to evaluate likely clinical benefit from PD-1/PD-L1 inhibitors, whether administered alone or in combination with chemotherapy. The platform analyzes protein-expression patterns, connects findings to biological resistance signals and presents physicians with practical decision-support scoring. For executives prioritizing validated clinical utility, broader biological context and workflow-ready reporting, OncoHost represents a strong choice for advancing precision oncology initiatives.
...Read more
Precision Oncology Solution Info
Q1
What distinguishes OncoHost among Top Precision Oncology Solutions providers?
OncoHost has earned recognition among Top Precision Oncology Solutions providers through its host-response approach to cancer treatment planning. Rather than focusing only on tumor biology, the company analyzes the patient’s systemic biological response using advanced proteomics and AI-driven analytics. Its flagship platform, PROphet®, evaluates thousands of plasma proteins from a single blood sample to predict treatment benefit, resistance mechanisms and potential toxicities before therapy begins. OncoHost also differentiates itself through explainable clinical insights that help oncologists make more informed immunotherapy decisions across multiple cancer indications.
Q2
How does OncoHost approach precision oncology and immunotherapy prediction?
Patient-centered biological analysis forms the foundation of the company’s scientific strategy. Unlike many Precision Oncology Solutions providers that rely primarily on tumor genetics or PD-L1 scoring, OncoHost evaluates the interaction between tumor biology, immune response and host-system dynamics. Its PROphetNSCLC™ platform supports treatment planning for advanced non-small cell lung cancer by combining proteomic analysis with machine learning to predict whether patients are likely to benefit from immune checkpoint inhibitors. This broader biological perspective helps clinicians move beyond static molecular snapshots toward more adaptive and personalized treatment planning.
Q3
Why is OncoHost relevant to the future of cancer treatment?
Precision medicine continues to shift toward predictive and individualized treatment selection, particularly in immuno-oncology. OncoHost addresses this need through Precision Oncology Solutions designed to improve therapeutic decision-making before treatment starts. Its technology helps identify patients who may not respond to immunotherapy despite favorable biomarker profiles, reducing unnecessary treatment exposure and supporting more personalized care strategies. The company’s work also aligns with growing healthcare interest in blood-based diagnostics, AI-supported oncology and dynamic biomarker analysis capable of improving treatment accuracy and patient outcomes.
Q4
What role does artificial intelligence play in OncoHost’s platform?
AI integration remains central to OncoHost’s clinical innovation model. The company combines machine learning, bioinformatics and plasma proteomics to generate predictive insights that support oncologists during treatment selection. Its algorithms analyze large-scale proteomic patterns associated with therapeutic response, resistance and immune-related adverse events across cancer populations. Precision Oncology Solutions providers often differentiate themselves through data interpretation capabilities, and OncoHost strengthens its position through explainable AI models designed to provide clinically actionable guidance rather than isolated risk scores alone.
Q5
How does OncoHost support oncologists and clinical research programs?
Collaborative scientific engagement plays an important role in OncoHost’s development strategy. The company supports physicians through clinically validated diagnostic tools designed to complement existing genomic and biomarker testing workflows. Its ongoing PROPHETIC study, one of the largest prospective trials in the field, continues to expand understanding of host-response biology across multiple cancer types. Among Precision Oncology Solutions providers, OncoHost also stands out for maintaining collaborations with research institutions, healthcare organizations and pharmaceutical partners focused on advancing translational oncology research and biomarker-driven therapeutic development.
Q6
Why has OncoHost gained recognition in precision oncology?
Industry recognition for OncoHost reflects its contribution to advancing personalized cancer treatment through proteomics and AI-powered clinical decision support. Life Sciences Review recognized the company as a Top Precision Oncology Solution provider for its innovative PROphet® platform and its ability to improve immunotherapy planning using systemic host-response analysis. Its continued expansion into renal cell carcinoma, melanoma and immune-related toxicity prediction further strengthens the platform’s clinical relevance. This combination of proteomic science, machine learning and patient-centered oncology innovation continues to reinforce OncoHost’s standing within Precision Oncology Solutions.
